Clinical trials
ST Elevation Myocardial Infarction trials in Israel
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Unknown status | 7 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sheba Medical Center | 3 |
| Assaf-Harofeh Medical Center | 2 |
| Tel-Aviv Sourasky Medical Center | 2 |
| BIOTRONIK Israel | 1 |
| BSP Biological Signal Processing Ltd. | 1 |
| Bellerophon BCM LLC | 1 |
| Bnai Zion Medical Center | 1 |
| Faraday Pharmaceuticals, Inc. | 1 |
| GlaxoSmithKline | 1 |
| HaEmek Medical Center, Israel | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| ST Elevation Myocardial Infarction | 20 |
| Myocardial Infarction | 5 |
| Non-ST Elevated Myocardial Infarction | 5 |
| Acute Coronary Syndrome | 4 |
| Coronary Artery Disease | 2 |
| Myocardial Ischemia | 2 |
| Angina Pectoris | 1 |
| Angina, Unstable | 1 |
| Cardiovascular Diseases | 1 |
| Chest Pain | 1 |
Trials
Showing 1 to 20 of 20. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.